Annexon, Inc. announced the appointment of Jamie Dananberg as Chief Medical Officer. On July 27, 2023, Dr. Dananberg commenced employment as Chief Medical Officer of the Company. Dr. Dananberg joins Annexon with more than 20 years of drug development experience across a variety of therapeutic areas in the pharmaceutical and biotechnology industries.

Most recently, he served as the chief medical officer for UNITY Biotechnology, where as one of its earliest employees, he built the medical and broader development organization. Prior to UNITY, Dr. Dananberg served as executive vice president at Takeda Pharmaceuticals in several roles including head, cardiovascular and metabolism therapeutic area, and as the head of both the therapeutic areas group and experimental/translational medicine. Before joining Takeda, he spent 16 years at Eli Lilly & Co.

where he brought more than 100 programs from discovery to development, leading and supporting efforts through all phases, including the launches of multiple commercial products. Before joining Lilly, he practiced medicine in endocrinology and metabolism and ran a basic science laboratory at the University of Michigan. Dr. Dananberg received his B.S. and M.D. degrees from Tufts University.